ReCode Therapeutics

About

ReCode Therapeutics is a genetic medicines company that specializes in mRNA and gene correction therapeutics.

Dallas,Texas,United States
51 - 100
https://recodetx.com

Highlights

Details

Last Funding Type: Series B
Last Funding Money Raised: $120M
Industries: Biopharma,Biotechnology,Genetics,Pharmaceutical
Founded date: Jan 1, 2015
Number Of Employee: 51 - 100
Operating Status: Active
Legal Name: ReCode Therapeutics, Inc.
Also Known As: ReCode

ReCode Therapeutics is a genetic medicines company that specializes in mRNA and gene correction therapeutics. Its selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a genetic medicines technology that enables precise delivery to target organs and cells beyond the liver.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

4

$412M

ReCode Therapeutics has raised a total of $412M in funding over 2 rounds. Their latest funding was raised on Jun 29, 2022 from a Series B round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Jun 29, 2022	Series B	$120M	5	Leaps by Bayer Matrix Capital Management	—	Detail
Oct 21, 2021	Series B	$210M	12	EcoR1 Capital Pfizer Venture Investments	—	Detail
Mar 26, 2020	Series A	$80M	6	Colt Ventures OrbiMed	—	Detail
Feb 8, 2019	Seed	$2M	—	—	—	Detail

Investors

Number of Lead Investors

Number of Investors

6

15

ReCode Therapeutics is funded by 15 investors. Leaps by Bayer and Matrix Capital Management are the most recent investors.

Investor Name	Lead Investor	Funding Round
Leaps by Bayer	Yes	Series B
Matrix Capital Management	Yes	Series B
EcoR1 Capital	Yes	Series B
Amgen Ventures	—	Series B
Pfizer Venture Investments	—	Series B
Sanofi Ventures	—	Series B
Colt Ventures	—	Series B
Hunt Technology Ventures	—	Series B
MPM Capital	—	Series B
NS Investment	—	Series B